Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Middle area:

Key facts & figures

Sanofi is a global healthcare company focused on patient needs. Our business includes pharmaceuticals (notably prescription drugs for diabetes, rare diseases, multiple sclerosis and oncology, consumer healthcare products and generics), vaccines and animal health.

Strong financial performance

2014 Net Sales
€33,770m

+4.9% at constant exchange rates (CER)
+2.5% on a reported basis

2014 Business EPS
€5.20

+7.3% at CER
+3.0% on a reported basis

 

SOLID GROWTH OF MOST BUSINESS AREAS

2014 sales by business areas
2014 sales by business areasChange at CER
Pharmaceuticals€27,720M+4.4%
Diabetes€7,273M+12.1%
Consumer Healthcare*€3,337M+16.5%
Genzyme**€2,604M+24.3%
Generics€1,805M+16.2%
Oncology€1,401M-2.5%
Established Rx brands€11,300M-6.7%
Vaccines€3,974M+7.2%
Animal Health€2,076M+6.7%

* Some products recorded in prescription pharmaceuticals in 2013 were transferred as Consumer Healthcare products and totaled €273m in FY 2013. When excluding this category change, sales of Consumer Healthcare grew +6.8% in FY 2014 at CER
** Rare Diseases and Multiple Sclerosis

 

A major biopharmaceutical player with an innovative R&D pipeline

€4,824M

invested in R&D in 2014

18 Launches

of new medicines and vaccines expected between 2014 and 2020,
of which 6 underway or imminent in 2015

 

Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad and Android!

 

Regeneron Alliance

 

IFRIC 21

New interpretation of tax levies - applicable as from January 1st, 2014

 

IAS19R

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013

 
 

© Sanofi 2004-2015 - All rights reserved - Update: June 17, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)